Patients with Hodgkin lymphoma (HL) who relapse after stem cell transplantation require accurate assessment of disease to develop realistic treatment goals and devise an appropriate therapeutic strategy. In this activity, Dr. Alison J. Moskowitz, Clinical Director of the Lymphoma Inpatient Unit at Memorial Sloan Kettering Cancer Center, reviews methods for prognosticating patients who relapse after transplant, as well as treatment options based on a combination of patient-related factors, disease biology, and practical treatment goals.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Takeda Oncology

Adaptive treatment strategies in Hodgkin lymphoma (HL) have the potential to individualize therapy through outcomes-based modifications. In this activity, Dr. Peter Johnson, Professor of Medical Oncology at the University of Southampton in the United Kingdom, discusses the current landscape of positron emission tomography (PET)-adapted therapy, including investigational treatment pathways and their impact on response rates and survival outcomes. In addition, Dr. Johnson will describe the utility of interim PET among currently recognized prognostic factors to help providers understand the practical application of PET-adapted therapy.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Takeda Oncology

Join Robert Chen, MD, of the Department of Hematology/HCT at the City of Hope Medical Center for a discussion regarding the latest strategies for salvage therapy at relapse in Hodgkin lymphoma.